Increasing incidence of bloodstream infections with Enterobacterales resistant to carbapenem antibiotics poses a significant threat to patients and healthcare systems in the EU/EEA. Carbapenem-resistant Enterobacterales (CRE), including carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Escherichia coli, pose a major risk to patients and healthcare systems in the EU/EEA. In fact, according to an updated ECDC risk assessment the epidemiological situation has been deteriorating since 2019. Carbapenem-resistant K. pneumoniae bloodstream infections have surged in 23 EU member states, driven by the continued spread of multidrug-resistant high-risk lineages in hospitals. In addition, some K. pneumoniae lineages that are more likely to cause severe diseases have also become resistant to carbapenems, including the hypervirulent lineage K. pneumoniae ST23. Newly emerging carbapenem-resistant Enterobacterales species (other than K. pneumoniae) are also spreading in hospitals. Furthermore, isolates and small clusters of certain carbapenem-resistant E. coli strains are increasingly being detected, posing a risk for spread in the community. These findings indicate a high probability of further spread of CRE in the EU/EEA, both in hospital settings and in community, a worrying trend since CRE infections are linked to high mortality. Even though several new antibiotics are available, treatment options remain limited overall. Immediate action is essential to control this problem and protect patients from infections that are becoming increasingly difficult to treat, says Piotr Kramarz, ECDC Chief Scientist.
Voir les recommandations de l’ECDC aux pays de l’Union européenne à : https://www.ecdc.europa.eu/en/publications-data/carbapenem-resistant-enterobacterales-rapid-risk-assessment-third-update